Pharmafile Logo
Pharmafocus logo
Advanced Search

Novartis

Showing 15 posts of 823 posts found.

novartis_window

Novartis’ drug doubly effective as chemotherapy for treating lung cancer

December 8, 2016
NSCLC, Novartis, chemotherapy

Novartis have released that its drug, Zykadia, in Phase III trials, was twice as effective at slowing progression in advanced …

News
novartis_building

Novartis posts 82% remission rate in CAR T paediatric study

December 5, 2016
Research and Development, Sales and Marketing CAR T, CAR-T, Novartis, leukaemia, paediatric

Novartis has released the results of its global, paediatric study of the treatment of leukaemia in children and young adults …

News
actinium_pharma

Actinium snatches up ex-Novartis clinical manager

November 29, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Actinium, Novartis, appointment

Actinium Pharmaceuticals has appointed Gregory Bergonio to the position of director of Clinical Operations, where he will first guide the …

Appointment
novartis_hq_day

Novartis in $665 million deal for Selexys

November 21, 2016
Sales and Marketing Novartis, SelG1, selexys

Novartis have confirmed the acquisition of Selexys Pharmaceuticals, after Selexys received positive results from a Phase II trial. Novartis had …

News
amgen_hq

Amgen boosted in race to market for migraine drug

November 17, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Amgen, Novartis, erenumab, migraine, phase III

Amgen released positive results from their second Phase III trial for experimental migraine drug, known as erenumab, which it is …

News

Novartis reportedly in talks to acquire Amneal in $8 billion deal

November 15, 2016
Manufacturing and Production, Sales and Marketing Amneal pharmaceuticals, Novartis, joe jimenez

Novartis are said to be eyeing a deal for Amneal pharmaceuticals in order to bolster its Sandoz generics business. Bloomsberg …

News

Novartis reveals positive three-year efficacy data for psoriatic arthritis drug

November 15, 2016
Manufacturing and Production, Research and Development Cosentyx, Novartis, psoriatic arthritis

Novartis has claimed that its Cosentyx (secukinumab) treatment is now the first approved fully human interleukin-17A (IL-17A) inhibitor to demonstrate …

News

Experimental Novartis leukaemia and mastocytosis drug gets FDA Priority Review

November 14, 2016
Research and Development, Sales and Marketing FDA, Novartis, acute myeloid leukaemia

The US FDA has granted Priority Review status to Novartis’ experimental drug PKC412 (midostaurin) as a treatment for advanced systemic …

News

Pfizer’s breast cancer drug gets EU approval

November 10, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing EMA, EU, Novartis, Pfizer, ibrance

Pfizer is celebrating the approval by the European Union of its breast cancer drug Ibrance, following a positive recommendation from …

News
novartis_outside_1

Novartis breast cancer drug secures FDA fast-track status

November 1, 2016
Manufacturing and Production, Sales and Marketing Novartis, Pfizer, ibrance, letrozole, riboclib

Novartis has announced that its product ribociclib (LEE011) has been granted fast-track review status as a first-line treatment of advanced …

News
cynthia_chiaramitara

Novartis elects new MD for UK plant

October 28, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Novartis, appointment

Novartis has named Cynthia Chiaramitara as managing director of its plant in Grimsby, UK. She will take on the role …

Appointment
novartis_outside_1

Novartis rides out fiscal hardship to beat Q3 forecasts

October 25, 2016
Manufacturing and Production, Sales and Marketing Entresto, Gleevec, Novartis

Novartis has beaten its third-quarter sales projections, announcing that new product growth and cost cuts managed to carry the company …

News
novartis_window

Novartis in collaboration deal worth potential $1.2 billion with Cerulean

October 20, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cerulean, NDC, Novartis

Novartis has signed an agreement with Cerulean Pharma, worth a potential $1.2 billion depending on milestones met, to co-develop nanoparticle-drug …

News

Novartis’ Zykadia more effective than chemo, new study shows

October 13, 2016
Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Alcensa, Novartis, Roche, Xalkori, ceritinib, crizotinib, lung cancer, zykadia

Phase III results for Novartis’ cancer drug Zykadia (ceritinib) have revealed it as more effective than chemo at halting progression …

News
novartis_building

Novartis’ new drug muscles in on Pfizer’s territory

October 10, 2016
Sales and Marketing Eli Lilly, Novartis, Pfizer, ibrance, ribociclib

A drug developed by Novartis, ribociclib, when combined with an older drug, letrozole, has been shown to reduce risk of progression …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025